Latest news with #Solventum
Yahoo
5 days ago
- Business
- Yahoo
What to Expect From Solventum's Q2 2025 Earnings Report
Solventum Corporation (SOLV), based in Maplewood, Minnesota, is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs. With a market cap of $12.6 billion, the company's broad portfolio of solutions leverages material and data science, clinical research, and digital capabilities. Solventum operates in the areas of separation and purification, health information, medical solutions, medical device components, and the oral care market. The leading global healthcare company is expected to announce its fiscal second-quarter earnings for 2025 after the market closes on Thursday, Aug. 7. Ahead of the event, analysts expect SOLV to report a profit of $1.45 per share on a diluted basis, down 7.1% from $1.56 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the full year, analysts expect SOLV to report EPS of $5.58, down 16.7% from $6.70 in fiscal 2024. However, its EPS is expected to rise 3.1% year-over-year to $5.75 in fiscal 2026. SOLV stock has outperformed the S&P 500 Index's ($SPX) 14.5% gains over the past 52 weeks, with shares up 31.4% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund's (XLV) 8.3% dip over the same time frame. On May 8, SOLV reported its Q1 results, and its shares closed up by 11.9% in the following two trading sessions. Its adjusted EPS of $1.34 beat Wall Street's expectations of $1.19. The company's revenue was $2.1 billion, exceeding Wall Street forecasts of $2 billion. SOLV expects full-year adjusted EPS in the range of $5.45 to $5.65. Analysts' consensus opinion on SOLV stock is reasonably bullish, with an overall 'Moderate Buy' rating. Out of 12 analysts covering the stock, four advise a 'Strong Buy' rating, seven give a 'Hold,' and one recommends a 'Strong Sell.' SOLV's average analyst price target is $85.50, indicating a potential upside of 14.9% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-07-2025
- Business
- Yahoo
Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Healthcare Technology for Patients company Tandem Diabetes (NASDAQ:TNDM) fell 3.3%. Is now the time to buy Tandem Diabetes? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Diversified company Solventum (NYSE:SOLV) fell 3.1%. Is now the time to buy Solventum? Access our full analysis report here, it's free. Surgical Equipment & Consumables - Specialty company LeMaitre (NASDAQ:LMAT) fell 3%. Is now the time to buy LeMaitre? Access our full analysis report here, it's free. Drug Development Inputs & Services company UFP Technologies (NASDAQ:UFPT) fell 3.4%. Is now the time to buy UFP Technologies? Access our full analysis report here, it's free. Medical Devices & Supplies - Cardiology, Neurology, Vascular company Artivion (NYSE:AORT) fell 3%. Is now the time to buy Artivion? Access our full analysis report here, it's free. UFP Technologies's shares are very volatile and have had 22 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. UFP Technologies is down 1% since the beginning of the year, and at $243.73 per share, it is trading 32% below its 52-week high of $358.42 from September 2024. Investors who bought $1,000 worth of UFP Technologies's shares 5 years ago would now be looking at an investment worth $5,398. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bangkok Post
09-07-2025
- Business
- Bangkok Post
Solventum Launches Two Dental Innovations in Thailand
Bangkok, July 7, 2025 – Solventum, a leading global healthcare innovation company, proudly marked its first anniversary of operations in Thailand with the unveiling of two cutting-edge dental products: 3M™ Clinpro™ Clear Fluoride Treatment and 3M™ Filtek™ Easy Match. The launch took place recently at the Thailand Dental Association (TDA) 2025 exhibition at the Bangkok Convention Centre at CentralWorld, underscoring Solventum's more than 70-year legacy of leadership in the dental industry. "The name 'Solventum' is derived from 'Solving with Momentum,' reflecting our belief that excellent oral healthcare begins with truly understanding and addressing the needs of both dental professionals and patients," stated Miss Meifang Sit, Marketing Manager, Emerging Asia (Southeast Asia, Hong Kong and Taiwan), Solventum Dental Solutions."The introduction of 3M™ Clinpro™ Clear and 3M™ Filtek™ Easy Match is more than just product innovation; it's a delivery of our promise that 'We never stop solving for you.' These solutions reflect Solventum's 'Success Simplified' philosophy by streamlining dental workflows and enhancing ease of use. The result is faster, more comfortable, and more effective care—delivering meaningful benefits to both clinicians and patients, and elevating the entire oral care experience.' The two latest dental innovations include: 3M™ Clinpro™ Clear Fluoride Treatment: a water-based and resin-free formula designed for easy application. It quickly delivers fluoride, protecting your teeth with just a 15-minute contact time. Available in three pleasant flavours, it also stands out because it doesn't leave a sticky feeling or cause any yellow discoloration, making it an excellent choice 3M™ Filtek™ Easy Match: A restorative dental material that enables easy, intuitive shade selection and faster restoration without compromising on natural aesthetics and with the need for separate blocker. With just three shades, bright, natural and warm that can seamlessly used for both anterior and posterior teeth, blending effortlessly with surrounding natural tooth colour. Built with Solventum's proprietary True Nano technology, it offers exceptional strength, durability, polish retention and reliable aesthetic results. Miss Thamolwan Laovittayanurak, Business Leader Dental Solutions, Solventum Thailand, added, "On the occasion of our first anniversary in Thailand, we are immensely proud to introduce these two innovative products. They not only meet the operational demands of dental professionals but also reflect our patient-centric vision. This launch represents a significant milestone, showcasing Solventum's robust growth and commitment in Thailand." "For over 70 years, from 3M Healthcare to Solventum, we have earned trust as a leader in dental innovation. We continue to advance this expertise as a dedicated healthcare company, committed to inventing new solutions that address global health challenges," Miss Thamolwan continued."We adhere to the principles of 'listening and never stopping development,' paying close attention to real clinical contexts to deliver precise solutions that improve everyone healthier and create sustainable change." To ensure that its world-class products safely reach dental professionals and consumers nationwide, Solventum has partnered with DKSH as its official distributor in Thailand. "Products not sourced through official distribution channels may pose risks to user safety and reputation. Therefore, we strongly recommend purchasing products exclusively through DKSH to ensure the highest quality, safety, and efficacy in patient care," Miss Thamolwan emphasised.
Yahoo
06-07-2025
- Business
- Yahoo
Wells Fargo maintained a Buy rating on Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Brandon Couillard from Wells Fargo maintained a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO) with a price target of $570. Analyst Brandon Couillard noted the recent Amendment to the acquisition deal with Solventum Corp (NYSE:SOLV). The revised agreement excludes Solventum's lower-margin Drinking Water Filtration business from the acquisition, reducing the purchase price from about $4.1 billion to $4.0 billion. Couillard believes that this simplifies the transaction and also potentially accelerates its closing by the end of 2025, while improving the financial attractiveness of the deal. A workstation in a research lab stocked with laboratory products and services. The deal revision is expected to be accretive to Thermo Fisher Scientific Inc.'s (NYSE:TMO) earnings per share even after accounting for financing costs. The exclusion of the non-core Drinking Water business aligns with the focus of the company on higher-margin, higher-growth segments, supporting stronger earnings growth. In addition, Thermo Fisher Scientific Inc. (NYSE:TMO) has demonstrated consistent quarter-over-quarter improvement in core growth, with expectations of about 5% core growth in 2025. Moreover, its long-range plan aims to achieve robust organic growth of 7% to 9%, significant operational margin expansion, and double-digit growth in operating profits. Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading company in the life sciences and diagnostics industry. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
05-07-2025
- Business
- Yahoo
Solventum Amends Thermo Fisher Deal, Retains Water Filtration Business
Solventum Corporation (NYSE:SOLV) is one of the best new stocks to buy now. On June 25, Solventum announced an amendment to its transaction agreement with Thermo Fisher Scientific Inc. (NYSE:TMO). The revised agreement now excludes Solventum's drinking water filtration business from the assets being acquired by Thermo Fisher. Consequently, the cash consideration for the acquisition has been adjusted from ~$4.1 billion to $4 billion. The net proceeds from this sale are intended for debt reduction. This amendment is expected to streamline the transaction and accelerate its closure, which is still expected by the end of this year. Under the new terms, Thermo Fisher will be entitled to a payment of up to $75 million from Solventum. Keeping the Water Business is projected to increase Solventum's annual EPS gain by $0.15 to $0.2. A healthcare professional wearing a health communications device discussing patient data with a colleague. The terms of the amended agreement remain largely consistent with the initial agreement, with modifications specifically reflecting the exclusion of the Water Business. These adjustments include changes to non-compete clauses and related provisions, as well as certain reverse services, manufacturing, and supply agreements that will now support the retained Water Business. Solventum Corporation (NYSE:SOLV) is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address customer and patient needs internationally. Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services internationally. While we acknowledge the potential of SOLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
